Journal:

Article Title: Characteristics and Dynamics of Bacterial Populations during Postantibiotic Effect Determined by Flow Cytometry

doi:

Figure Lengend Snippet: MICs, multiples of MICs, and duration of PAEs for organism-antibiotic combinations studied by flow cytometry

Article Snippet: Growth curves from typical PAE experiments with ceftriaxone and ciprofloxacin (each at a concentration equivalent to twice the MIC) against E. coli are shown in Fig. A. table ft1 table-wrap mode="anchored" t5 TABLE 1 caption a7 Organism Antibiotic MIC (μg/ml) Multiple of MIC PAE (h) E. coli ATCC 25922 Ampicillin 2.0 2 −0.3 4 −0.4 8 −0.3 Ceftriaxone 0.03 2 −0.3 4 −0.2 8 −0.5 Gentamicin 1.0 1 0.7 2 0.6 Ciprofloxacin 0.015 1 1.5 2 2.7 Rifampin 16 1 0.6 2 1.5 P. aeruginosa ATCC 27853 Imipenem 2.0 2 1.3 4 1.9 8 2.6 Ciprofloxacin 0.5 2 0.7 Open in a separate window MICs, multiples of MICs, and duration of PAEs for organism-antibiotic combinations studied by flow cytometry fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window FIG. 1 caption a7 (A) A typical PAE experiment for E. coli ATCC 25922 after exposure to ceftriaxone or ciprofloxacin (each at a concentration equivalent to twice the MIC), as determined by viability counting.

Techniques:

Journal:

Article Title: Characteristics and Dynamics of Bacterial Populations during Postantibiotic Effect Determined by Flow Cytometry

doi:

Figure Lengend Snippet: (A) A typical PAE experiment for E. coli ATCC 25922 after exposure to ceftriaxone or ciprofloxacin (each at a concentration equivalent to twice the MIC), as determined by viability counting. As shown, no PAE was seen after ceftriaxone exposure, but ciprofloxacin induced a PAE of 1.9 h. The organisms were stained with propidium iodide and examined by fluorescence microscopy. (B through D) Photomicrographs of untreated control organisms (B), ceftriaxone-exposed organisms 35 min after drug removal (C), and ciprofloxacin-exposed organisms 270 min after drug removal (D). Both antibiotics induced filamentation, but this morphological form persisted past the classically defined PAE in organisms exposed to ciprofloxacin. Magnification, ×880.

Article Snippet: Growth curves from typical PAE experiments with ceftriaxone and ciprofloxacin (each at a concentration equivalent to twice the MIC) against E. coli are shown in Fig. A. table ft1 table-wrap mode="anchored" t5 TABLE 1 caption a7 Organism Antibiotic MIC (μg/ml) Multiple of MIC PAE (h) E. coli ATCC 25922 Ampicillin 2.0 2 −0.3 4 −0.4 8 −0.3 Ceftriaxone 0.03 2 −0.3 4 −0.2 8 −0.5 Gentamicin 1.0 1 0.7 2 0.6 Ciprofloxacin 0.015 1 1.5 2 2.7 Rifampin 16 1 0.6 2 1.5 P. aeruginosa ATCC 27853 Imipenem 2.0 2 1.3 4 1.9 8 2.6 Ciprofloxacin 0.5 2 0.7 Open in a separate window MICs, multiples of MICs, and duration of PAEs for organism-antibiotic combinations studied by flow cytometry fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window FIG. 1 caption a7 (A) A typical PAE experiment for E. coli ATCC 25922 after exposure to ceftriaxone or ciprofloxacin (each at a concentration equivalent to twice the MIC), as determined by viability counting.

Techniques: Concentration Assay, Staining, Fluorescence, Microscopy, Control

Journal:

Article Title: Characteristics and Dynamics of Bacterial Populations during Postantibiotic Effect Determined by Flow Cytometry

doi:

Figure Lengend Snippet: Histograms showing a comparison of the size distribution (FSC-H) (left panels) and nucleic acid content (FL2-H) (middle panels) of E. coli during the PAE after exposure to ampicillin at a concentration equivalent to twice the MIC at 35 min after drug removal and after exposure to rifampin at a concentration equivalent to the MIC (lower panels) at 90 min after drug removal. Dotted-and-dashed lines, control organisms; solid lines, organisms previously exposed to the antibiotics. (Upper right graph) Progressive changes in size, compared to sizes of control organisms, as a function of time after previous exposure to ampicillin. (Lower right graph) Summary of the minimal changes in size that were noted after previous exposure to rifampin. The sizes of the antibiotic-treated organisms were compared to three size intervals derived from the control, which are described in text and shown in Fig. ​Fig.2.2. Open circles, bacteria in the PAE phase which were within 2 SDs of control size; solid squares, bacteria within 2 to 4 SDs; open squares, organisms >4 SDs from the control distribution.

Article Snippet: Growth curves from typical PAE experiments with ceftriaxone and ciprofloxacin (each at a concentration equivalent to twice the MIC) against E. coli are shown in Fig. A. table ft1 table-wrap mode="anchored" t5 TABLE 1 caption a7 Organism Antibiotic MIC (μg/ml) Multiple of MIC PAE (h) E. coli ATCC 25922 Ampicillin 2.0 2 −0.3 4 −0.4 8 −0.3 Ceftriaxone 0.03 2 −0.3 4 −0.2 8 −0.5 Gentamicin 1.0 1 0.7 2 0.6 Ciprofloxacin 0.015 1 1.5 2 2.7 Rifampin 16 1 0.6 2 1.5 P. aeruginosa ATCC 27853 Imipenem 2.0 2 1.3 4 1.9 8 2.6 Ciprofloxacin 0.5 2 0.7 Open in a separate window MICs, multiples of MICs, and duration of PAEs for organism-antibiotic combinations studied by flow cytometry fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window FIG. 1 caption a7 (A) A typical PAE experiment for E. coli ATCC 25922 after exposure to ceftriaxone or ciprofloxacin (each at a concentration equivalent to twice the MIC), as determined by viability counting.

Techniques: Comparison, Concentration Assay, Control, Derivative Assay, Bacteria

Journal:

Article Title: Characteristics and Dynamics of Bacterial Populations during Postantibiotic Effect Determined by Flow Cytometry

doi:

Figure Lengend Snippet: Histograms showing a comparison of the size distributions (FSC-H; left panels) and nucleic acid contents (FL2-H; middle panels) of E. coli during the PAE after exposure to ciprofloxacin at a concentration equivalent to the MIC and at a concentration equivalent to twice the MIC at 270 min after drug removal. Dotted-and-dashed lines, control organisms; solid lines, bacteria previously exposed to ciprofloxacin. Graphs (right panels) show progressive changes in size compared to sizes of controls. The sizes of antibiotic-treated organisms were compared to three control size intervals described in the text and shown in Fig. ​Fig.2.2. Open circles, bacteria within 2 SDs of control size; solid squares, bacteria within 2 to 4 SDs; open squares, organisms >4 SDs from the control distribution.

Article Snippet: Growth curves from typical PAE experiments with ceftriaxone and ciprofloxacin (each at a concentration equivalent to twice the MIC) against E. coli are shown in Fig. A. table ft1 table-wrap mode="anchored" t5 TABLE 1 caption a7 Organism Antibiotic MIC (μg/ml) Multiple of MIC PAE (h) E. coli ATCC 25922 Ampicillin 2.0 2 −0.3 4 −0.4 8 −0.3 Ceftriaxone 0.03 2 −0.3 4 −0.2 8 −0.5 Gentamicin 1.0 1 0.7 2 0.6 Ciprofloxacin 0.015 1 1.5 2 2.7 Rifampin 16 1 0.6 2 1.5 P. aeruginosa ATCC 27853 Imipenem 2.0 2 1.3 4 1.9 8 2.6 Ciprofloxacin 0.5 2 0.7 Open in a separate window MICs, multiples of MICs, and duration of PAEs for organism-antibiotic combinations studied by flow cytometry fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window FIG. 1 caption a7 (A) A typical PAE experiment for E. coli ATCC 25922 after exposure to ceftriaxone or ciprofloxacin (each at a concentration equivalent to twice the MIC), as determined by viability counting.

Techniques: Comparison, Concentration Assay, Control, Bacteria

Journal:

Article Title: Characteristics and Dynamics of Bacterial Populations during Postantibiotic Effect Determined by Flow Cytometry

doi:

Figure Lengend Snippet: Histograms showing the size distributions (FSC-H; left panels) and nucleic acid contents (FL2-H; middle panels) of P. aeruginosa during the PAE after exposure to imipenem at a concentration equivalent to twice the MIC and to ciprofloxacin at a concentration equivalent to the MIC at 180 and 70 min after drug removal, respectively. Dotted-and-dashed lines, control organisms; solid lines, antibiotic-exposed organisms. The graphs (right panels) show progressive changes in size compared to sizes of controls. The sizes of antibiotic-treated organisms were compared to three control size intervals described in text and shown in Fig. ​Fig.2.2. Open circles, bacteria within 2 SDs of control size; solid squares, bacteria within 2 to 4 SDs; open squares, organisms >4 SDs from the control distribution.

Article Snippet: Growth curves from typical PAE experiments with ceftriaxone and ciprofloxacin (each at a concentration equivalent to twice the MIC) against E. coli are shown in Fig. A. table ft1 table-wrap mode="anchored" t5 TABLE 1 caption a7 Organism Antibiotic MIC (μg/ml) Multiple of MIC PAE (h) E. coli ATCC 25922 Ampicillin 2.0 2 −0.3 4 −0.4 8 −0.3 Ceftriaxone 0.03 2 −0.3 4 −0.2 8 −0.5 Gentamicin 1.0 1 0.7 2 0.6 Ciprofloxacin 0.015 1 1.5 2 2.7 Rifampin 16 1 0.6 2 1.5 P. aeruginosa ATCC 27853 Imipenem 2.0 2 1.3 4 1.9 8 2.6 Ciprofloxacin 0.5 2 0.7 Open in a separate window MICs, multiples of MICs, and duration of PAEs for organism-antibiotic combinations studied by flow cytometry fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window FIG. 1 caption a7 (A) A typical PAE experiment for E. coli ATCC 25922 after exposure to ceftriaxone or ciprofloxacin (each at a concentration equivalent to twice the MIC), as determined by viability counting.

Techniques: Concentration Assay, Control, Bacteria

Journal: Chemical communications (Cambridge, England)

Article Title: Desferrioxamine:gallium-pluronic micelles increase outer membrane permeability and potentiate antibiotic activity against Pseudomonas aeruginosa †

doi: 10.1039/c8cc08134d

Figure Lengend Snippet: F127-DG2 increases the OM permeability of P. aeruginosa. (A) Targeted F127-DG2/TPE micelles exhibit greater binding to the OM of P. aeruginosa than untargeted F127/TPE micelles based on increased TPE fluorescence (blue). F127-DG2/TPE does not target E. coli due to lack of the necessary OM receptors. Positive control staining performed with FM 4-64FX (red). (B) OM permeabilization with F127-DG2 (64 µM) results in greater HI accumulation (red) in P. aeruginosa than unmodified F127 (64 µM) + DG (128 µM), while E. coli OM permeability is unchanged. Positive control staining performed with SYTO13 (green). (C) NCF hydrolysis occurs more rapidly in P. aeruginosa treated with F127-DG2 (128 µM) than unmodified F127 (128 µM) + DG (256 µM); E. coli OM permeability is unaffected by either polymer. Scale bars represent 2 µm.

Article Snippet: Neither F127-DG 2 nor F127 plus DG potentiated antibiotic activity against E. coli due to lack of the necessary OM receptors for DG. table ft1 table-wrap mode="anchored" t5 caption a7 P. aeruginosa E. coli Potentiator Antibiotic ATCC 27853 a PAO1 a MDR 2638 a MDR 3072 a MDR 24530 a ATCC 25922 a None ERY 256 256 512 256 512 32 RIF 32 16 8 16 16 4 VAN >1024 >1024 512 >1024 1024 128 F127-DG 2 ERY 64(0.38) 128(0.53) 64(0.25) 128(0.63) 256(0.53) 16(0.75) RIF 8(0.31) 8(0.56) 4(0.53) 8(0.56) 8(0.53) 4(1.25) VAN 32(0.16) 64(0.19) 64(0.19) 64(0.19) 128(0.25) 128(1.25) Open in a separate window a Inhibitory concentrations for antibiotics are given in μg mL −1 , followed by FICIs given in parentheses.

Techniques: Permeability, Binding Assay, Fluorescence, Positive Control, Staining, Polymer

Journal: Chemical communications (Cambridge, England)

Article Title: Desferrioxamine:gallium-pluronic micelles increase outer membrane permeability and potentiate antibiotic activity against Pseudomonas aeruginosa †

doi: 10.1039/c8cc08134d

Figure Lengend Snippet: Antimicrobial activity of F127-DG 2 or F127 + DG combined with selected antibiotics against P. aeruginosa and E. coli . The MIC of F127-DG 2 alone or free DG was greater than 1024 µM for all strains. FICI o 0.25 considered high synergistic activity, 0.25 o FICI o 0.75 considered moderate synergistic activity, and FICI > 0.75 considered no synergistic activity

Article Snippet: Neither F127-DG 2 nor F127 plus DG potentiated antibiotic activity against E. coli due to lack of the necessary OM receptors for DG. table ft1 table-wrap mode="anchored" t5 caption a7 P. aeruginosa E. coli Potentiator Antibiotic ATCC 27853 a PAO1 a MDR 2638 a MDR 3072 a MDR 24530 a ATCC 25922 a None ERY 256 256 512 256 512 32 RIF 32 16 8 16 16 4 VAN >1024 >1024 512 >1024 1024 128 F127-DG 2 ERY 64(0.38) 128(0.53) 64(0.25) 128(0.63) 256(0.53) 16(0.75) RIF 8(0.31) 8(0.56) 4(0.53) 8(0.56) 8(0.53) 4(1.25) VAN 32(0.16) 64(0.19) 64(0.19) 64(0.19) 128(0.25) 128(1.25) Open in a separate window a Inhibitory concentrations for antibiotics are given in μg mL −1 , followed by FICIs given in parentheses.

Techniques: Activity Assay

Journal: Chemical communications (Cambridge, England)

Article Title: Desferrioxamine:gallium-pluronic micelles increase outer membrane permeability and potentiate antibiotic activity against Pseudomonas aeruginosa †

doi: 10.1039/c8cc08134d

Figure Lengend Snippet: Survival of P. aeruginosa cells treated for 4 h shows bacteriostatic activity for ERY when combined with F127-DG2, while RIF and VAN combinations were bactericidal. (A) MHA plates at 0 and 4 hour for cultures of P. aeruginosa treated with F127-DG2 combined with ERY, RIF, or VAN. (A) F127-DG2 combined with ERY is bacteriostatic against P. aeruginosa whereas RIF or VAN are bactericidal. Unmodified F127 + DG combined with tested antibiotics did not result in inhibitory activity against P. aeruginosa and E. coli was also relatively unaffected by either formulation. Note: 128 µM F127-DG2 (or 128 µM F127+ 256 µM DG) and 96 µg mL−1 ERY, 12 µg mL−1 RIF, or 48 µg mL−1 were used against P. aeruginosa. One-way ANOVA performed for P. aeruginosa with F127-DG2 plus antibiotics relative to t = 0 h positive control, ***p < 0.001.

Article Snippet: Neither F127-DG 2 nor F127 plus DG potentiated antibiotic activity against E. coli due to lack of the necessary OM receptors for DG. table ft1 table-wrap mode="anchored" t5 caption a7 P. aeruginosa E. coli Potentiator Antibiotic ATCC 27853 a PAO1 a MDR 2638 a MDR 3072 a MDR 24530 a ATCC 25922 a None ERY 256 256 512 256 512 32 RIF 32 16 8 16 16 4 VAN >1024 >1024 512 >1024 1024 128 F127-DG 2 ERY 64(0.38) 128(0.53) 64(0.25) 128(0.63) 256(0.53) 16(0.75) RIF 8(0.31) 8(0.56) 4(0.53) 8(0.56) 8(0.53) 4(1.25) VAN 32(0.16) 64(0.19) 64(0.19) 64(0.19) 128(0.25) 128(1.25) Open in a separate window a Inhibitory concentrations for antibiotics are given in μg mL −1 , followed by FICIs given in parentheses.

Techniques: Activity Assay, Formulation, Positive Control

Journal:

Article Title: A Mouse Mammary Epithelial Cell Model to Identify Molecular Mechanisms Regulating Breast Cancer Progression

doi: 10.1016/S0076-6879(08)01604-2

Figure Lengend Snippet: Drug selection for stable transfection of iMMECs

Article Snippet: The drug used for selection is routinely kept in the regular growth medium thereafter. table ft1 table-wrap mode="anchored" t5 caption a7 Drug Source Final concentration Geneticin Invitrogen 300 μ g/ml Zeocin Invitrogen 100 μ g/ml Open in a separate window Drug selection for stable transfection of iMMECs table ft1 table-wrap mode="anchored" t5 caption a7 Genotype Transgene iMMEC cell line name Wild-type WTA (or 21), WTB, WTC, WTD, WT3, WT5 Wild-type pcDNA3.1 vector WTA.V, WT3.V Wild-type Bcl-2 (human) WTA.B1, WTA.B4, WT3.B1, WT3.B2, WT3.B3, WT3.B8 Wild-type EGFP-LC3 WTA-LC3, WT3-LC3 Wild-type Bcl-2, EGFP-LC3 WTA.B4-LC3, WT3.B3-LC3 Wild-type HER2/neu (human, wild-type) WTA.H2, WTA.H3 Wild-type myr -Akt WTA.A5, WTA.A7 Wild-type H-Ras V12 WTA.R3, WTA.R5 beclin1 +/− BLN2 (or 2.1), BLN4 beclin1 +/− pcDNA3.1 vector BLN2.V beclin1 +/− Bcl-2 BLN2.B2, BLN2.B4, BLN2.B5, BLN2.B8 beclin1 +/− EGFP-LC3 BLN2-LC3 beclin1 +/− Bcl-2, EGFP-LC3 BLN2.B4-LC3.5 Open in a separate window Mouse (C57BL/6, Wild-type or mutant) mammary epithelial cell lines, E1A and p53DD-derived ( Karantza-Wadsworth et al., 2007 ) 3.4.

Techniques: Selection, Stable Transfection, Concentration Assay

Journal: Breast cancer research and treatment

Article Title: Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43

doi: 10.1007/s10549-013-2755-z

Figure Lengend Snippet: CONSORT: NSABP B-43 IHC immunohistochemistry, FISH fluorescence in situ hybridization

Article Snippet: For patients who have hormone receptor-positive DCIS, hormonal therapy should be given for a minimum of 5 years by investigator discretion ( , CONSORT; , Schema). fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window caption a7 CONSORT: NSABP B-43 IHC immunohistochemistry, FISH fluorescence in situ hybridization fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window caption a7 Schema NSABP B-43

Techniques: Immunohistochemistry, Fluorescence, In Situ Hybridization

Journal: Antimicrobial Agents and Chemotherapy

Article Title: In Vivo Pharmacodynamics of New Lipopeptide MX-2401 ▿

doi: 10.1128/AAC.00238-10

Figure Lengend Snippet: Plasma MX-2401 concentrations after single s.c. administrations of MX-2401 at 2.5, 10, and 40 mg/kg to neutropenic infected mice. The error bars represent standard deviations.

Article Snippet: The MICs were 2- to 8-fold lower for pneumococci than for staphylococci. table ft1 table-wrap mode="anchored" t5 TABLE 1. caption a7 Study organism MIC (μg/ml) MX-2401 Penicillin a S. aureus ATCC 29213 2.0 0.5 (MSSA) ATCC 33591 2.0 R (MRSA) ATCC 6538P 1.0 0.12 (MSSA) UW 31005 2.0 R (MSSA) UW 307109 2.0 R (MRSA) S. pneumoniae ATCC 10813 0.25 0.008 (PSSP) CDC 1020 0.5 2.0 (PRSP) CDC 1199 0.25 1.0 (PRSP) CDC 1329 0.25 2.0 (PRSP) CDC 146 0.5 4.0 (PSRP) Open in a separate window a PSSP, penicillin-susceptible S. pneumoniae ; PRSP, penicillin-resistant S. pneumoniae .

Techniques: Infection

Journal: Antimicrobial Agents and Chemotherapy

Article Title: In Vivo Pharmacodynamics of New Lipopeptide MX-2401 ▿

doi: 10.1128/AAC.00238-10

Figure Lengend Snippet: Killing and regrowth of S. pneumoniae ATCC 10813 (A), S. aureus ATCC 29213 (B), and S. aureus ATCC 33591 (C) over time in the thighs of neutropenic mice after exposure to a single s.c. dose of MX-2401. The error bars represent standard deviations.

Article Snippet: The MICs were 2- to 8-fold lower for pneumococci than for staphylococci. table ft1 table-wrap mode="anchored" t5 TABLE 1. caption a7 Study organism MIC (μg/ml) MX-2401 Penicillin a S. aureus ATCC 29213 2.0 0.5 (MSSA) ATCC 33591 2.0 R (MRSA) ATCC 6538P 1.0 0.12 (MSSA) UW 31005 2.0 R (MSSA) UW 307109 2.0 R (MRSA) S. pneumoniae ATCC 10813 0.25 0.008 (PSSP) CDC 1020 0.5 2.0 (PRSP) CDC 1199 0.25 1.0 (PRSP) CDC 1329 0.25 2.0 (PRSP) CDC 146 0.5 4.0 (PSRP) Open in a separate window a PSSP, penicillin-susceptible S. pneumoniae ; PRSP, penicillin-resistant S. pneumoniae .

Techniques:

Journal: Antimicrobial Agents and Chemotherapy

Article Title: In Vivo Pharmacodynamics of New Lipopeptide MX-2401 ▿

doi: 10.1128/AAC.00238-10

Figure Lengend Snippet: Relationship between PK/PD indices for MX-2401 and efficacy against S. pneumoniae ATCC 10813 (A) and S. aureus ATCC 29213 (B) in the thighs of neutropenic mice.

Article Snippet: The MICs were 2- to 8-fold lower for pneumococci than for staphylococci. table ft1 table-wrap mode="anchored" t5 TABLE 1. caption a7 Study organism MIC (μg/ml) MX-2401 Penicillin a S. aureus ATCC 29213 2.0 0.5 (MSSA) ATCC 33591 2.0 R (MRSA) ATCC 6538P 1.0 0.12 (MSSA) UW 31005 2.0 R (MSSA) UW 307109 2.0 R (MRSA) S. pneumoniae ATCC 10813 0.25 0.008 (PSSP) CDC 1020 0.5 2.0 (PRSP) CDC 1199 0.25 1.0 (PRSP) CDC 1329 0.25 2.0 (PRSP) CDC 146 0.5 4.0 (PSRP) Open in a separate window a PSSP, penicillin-susceptible S. pneumoniae ; PRSP, penicillin-resistant S. pneumoniae .

Techniques:

Journal: Antimicrobial Agents and Chemotherapy

Article Title: In Vivo Pharmacodynamics of New Lipopeptide MX-2401 ▿

doi: 10.1128/AAC.00238-10

Figure Lengend Snippet: Dose-response relationships for MX-2401 against multiple strains of S. pneumoniae and S. aureus in the thighs of neutropenic mice. Each point represents the mean of 3 mice. The error bars represent standard deviations.

Article Snippet: The MICs were 2- to 8-fold lower for pneumococci than for staphylococci. table ft1 table-wrap mode="anchored" t5 TABLE 1. caption a7 Study organism MIC (μg/ml) MX-2401 Penicillin a S. aureus ATCC 29213 2.0 0.5 (MSSA) ATCC 33591 2.0 R (MRSA) ATCC 6538P 1.0 0.12 (MSSA) UW 31005 2.0 R (MSSA) UW 307109 2.0 R (MRSA) S. pneumoniae ATCC 10813 0.25 0.008 (PSSP) CDC 1020 0.5 2.0 (PRSP) CDC 1199 0.25 1.0 (PRSP) CDC 1329 0.25 2.0 (PRSP) CDC 146 0.5 4.0 (PSRP) Open in a separate window a PSSP, penicillin-susceptible S. pneumoniae ; PRSP, penicillin-resistant S. pneumoniae .

Techniques:

Journal: Antimicrobial Agents and Chemotherapy

Article Title: In Vivo Pharmacodynamics of New Lipopeptide MX-2401 ▿

doi: 10.1128/AAC.00238-10

Figure Lengend Snippet: Dose-response relationships for 72-hour dosing of MX-2401 against S. pneumoniae ATCC 10813 in the thighs and lungs of normal and neutropenic mice. The error bars represent standard deviations.

Article Snippet: The MICs were 2- to 8-fold lower for pneumococci than for staphylococci. table ft1 table-wrap mode="anchored" t5 TABLE 1. caption a7 Study organism MIC (μg/ml) MX-2401 Penicillin a S. aureus ATCC 29213 2.0 0.5 (MSSA) ATCC 33591 2.0 R (MRSA) ATCC 6538P 1.0 0.12 (MSSA) UW 31005 2.0 R (MSSA) UW 307109 2.0 R (MRSA) S. pneumoniae ATCC 10813 0.25 0.008 (PSSP) CDC 1020 0.5 2.0 (PRSP) CDC 1199 0.25 1.0 (PRSP) CDC 1329 0.25 2.0 (PRSP) CDC 146 0.5 4.0 (PSRP) Open in a separate window a PSSP, penicillin-susceptible S. pneumoniae ; PRSP, penicillin-resistant S. pneumoniae .

Techniques:

Journal:

Article Title: In Vivo Pharmacodynamic Activity of the Glycopeptide Dalbavancin ▿

doi: 10.1128/AAC.01264-06

Figure Lengend Snippet: In vitro activity of dalbavancin against S. pneumoniae and S. aureus strains

Article Snippet: Beta-lactam resistance did not affect the in vitro potency of dalbavancin. table ft1 table-wrap mode="anchored" t5 TABLE 1. caption a7 Organism Dalbavancin MIC/MBC (mg/liter) MIC (mg/liter) Penicillin Methicillin S. pneumoniae strain 1199 0.004/0.004 1.0 1293 0.004/0.004 2.0 1325 0.008/0.008 2.0 1329 0.008/0.008 2.0 ATCC 10813 0.03/0.03 0.008 S. aureus strain ATCC 25923 0.12/0.50 0.12 33591 0.12/0.25 >8.0 31005 0.06/0.12 0.12 MRSA 0.06/0.25 >8.0 Smith 0.06/0.25 0.12 307109 0.06/0.12 >8.0 Open in a separate window In vitro activity of dalbavancin against S. pneumoniae and S. aureus strains

Techniques: In Vitro, Activity Assay

Journal:

Article Title: In Vivo Pharmacodynamic Activity of the Glycopeptide Dalbavancin ▿

doi: 10.1128/AAC.01264-06

Figure Lengend Snippet: Serum PKs of dalbavancin in neutropenic infected mice following the administration of six twofold escalating doses ranging from 2.5 to 80 mg/kg intraperitoneally. Each datum point represents the mean and standard deviation for three mice. t1/2, half-life.

Article Snippet: Beta-lactam resistance did not affect the in vitro potency of dalbavancin. table ft1 table-wrap mode="anchored" t5 TABLE 1. caption a7 Organism Dalbavancin MIC/MBC (mg/liter) MIC (mg/liter) Penicillin Methicillin S. pneumoniae strain 1199 0.004/0.004 1.0 1293 0.004/0.004 2.0 1325 0.008/0.008 2.0 1329 0.008/0.008 2.0 ATCC 10813 0.03/0.03 0.008 S. aureus strain ATCC 25923 0.12/0.50 0.12 33591 0.12/0.25 >8.0 31005 0.06/0.12 0.12 MRSA 0.06/0.25 >8.0 Smith 0.06/0.25 0.12 307109 0.06/0.12 >8.0 Open in a separate window In vitro activity of dalbavancin against S. pneumoniae and S. aureus strains

Techniques: Infection, Standard Deviation

Journal:

Article Title: In Vivo Pharmacodynamic Activity of the Glycopeptide Dalbavancin ▿

doi: 10.1128/AAC.01264-06

Figure Lengend Snippet: Impacts of serum, serum ultrafiltrate, and albumin on in vitro activity of dalbavancin against selected S. aureus strains

Article Snippet: Beta-lactam resistance did not affect the in vitro potency of dalbavancin. table ft1 table-wrap mode="anchored" t5 TABLE 1. caption a7 Organism Dalbavancin MIC/MBC (mg/liter) MIC (mg/liter) Penicillin Methicillin S. pneumoniae strain 1199 0.004/0.004 1.0 1293 0.004/0.004 2.0 1325 0.008/0.008 2.0 1329 0.008/0.008 2.0 ATCC 10813 0.03/0.03 0.008 S. aureus strain ATCC 25923 0.12/0.50 0.12 33591 0.12/0.25 >8.0 31005 0.06/0.12 0.12 MRSA 0.06/0.25 >8.0 Smith 0.06/0.25 0.12 307109 0.06/0.12 >8.0 Open in a separate window In vitro activity of dalbavancin against S. pneumoniae and S. aureus strains

Techniques: In Vitro, Activity Assay

Journal:

Article Title: In Vivo Pharmacodynamic Activity of the Glycopeptide Dalbavancin ▿

doi: 10.1128/AAC.01264-06

Figure Lengend Snippet: Impacts of single doses of dalbavancin on organism burden in thighs of neutropenic mice infected with either S. pneumoniae ATCC 10813 (left panel) or S. aureus ATCC 29213 (right panel). Mice received either no drug or one of five twofold-increasing dose levels of dalbavancin administered via the intraperitoneal route. The microbiologic burden was determined by plate counts of thigh homogenates at selected time points over 96 h. Each symbol represents a different dose level. Each datum point represents the mean and standard deviation for four thighs.

Article Snippet: Beta-lactam resistance did not affect the in vitro potency of dalbavancin. table ft1 table-wrap mode="anchored" t5 TABLE 1. caption a7 Organism Dalbavancin MIC/MBC (mg/liter) MIC (mg/liter) Penicillin Methicillin S. pneumoniae strain 1199 0.004/0.004 1.0 1293 0.004/0.004 2.0 1325 0.008/0.008 2.0 1329 0.008/0.008 2.0 ATCC 10813 0.03/0.03 0.008 S. aureus strain ATCC 25923 0.12/0.50 0.12 33591 0.12/0.25 >8.0 31005 0.06/0.12 0.12 MRSA 0.06/0.25 >8.0 Smith 0.06/0.25 0.12 307109 0.06/0.12 >8.0 Open in a separate window In vitro activity of dalbavancin against S. pneumoniae and S. aureus strains

Techniques: Infection, Standard Deviation

Journal:

Article Title: In Vivo Pharmacodynamic Activity of the Glycopeptide Dalbavancin ▿

doi: 10.1128/AAC.01264-06

Figure Lengend Snippet: Impact of dalbavancin dosing interval on the in vivo efficacy of dalbavancin against S. pneumoniae ATCC 10813 (left panel) or S. aureus ATCC 29213 (right panel) in neutropenic mice. Five total dose levels were fractionated over a 144-h study period. Each symbol represents one of four dosing intervals. Each datum point represents the mean and standard deviation log10 CFU/thigh for four thighs.

Article Snippet: Beta-lactam resistance did not affect the in vitro potency of dalbavancin. table ft1 table-wrap mode="anchored" t5 TABLE 1. caption a7 Organism Dalbavancin MIC/MBC (mg/liter) MIC (mg/liter) Penicillin Methicillin S. pneumoniae strain 1199 0.004/0.004 1.0 1293 0.004/0.004 2.0 1325 0.008/0.008 2.0 1329 0.008/0.008 2.0 ATCC 10813 0.03/0.03 0.008 S. aureus strain ATCC 25923 0.12/0.50 0.12 33591 0.12/0.25 >8.0 31005 0.06/0.12 0.12 MRSA 0.06/0.25 >8.0 Smith 0.06/0.25 0.12 307109 0.06/0.12 >8.0 Open in a separate window In vitro activity of dalbavancin against S. pneumoniae and S. aureus strains

Techniques: In Vivo, Standard Deviation

Journal:

Article Title: In Vivo Pharmacodynamic Activity of the Glycopeptide Dalbavancin ▿

doi: 10.1128/AAC.01264-06

Figure Lengend Snippet: Impact of dalbavancin dosing interval on efficacy against S. pneumoniae and S. aureus

Article Snippet: Beta-lactam resistance did not affect the in vitro potency of dalbavancin. table ft1 table-wrap mode="anchored" t5 TABLE 1. caption a7 Organism Dalbavancin MIC/MBC (mg/liter) MIC (mg/liter) Penicillin Methicillin S. pneumoniae strain 1199 0.004/0.004 1.0 1293 0.004/0.004 2.0 1325 0.008/0.008 2.0 1329 0.008/0.008 2.0 ATCC 10813 0.03/0.03 0.008 S. aureus strain ATCC 25923 0.12/0.50 0.12 33591 0.12/0.25 >8.0 31005 0.06/0.12 0.12 MRSA 0.06/0.25 >8.0 Smith 0.06/0.25 0.12 307109 0.06/0.12 >8.0 Open in a separate window In vitro activity of dalbavancin against S. pneumoniae and S. aureus strains

Techniques:

Journal:

Article Title: In Vivo Pharmacodynamic Activity of the Glycopeptide Dalbavancin ▿

doi: 10.1128/AAC.01264-06

Figure Lengend Snippet: Relationship between the free-drug 24-h AUC/MIC, Cmax/MIC, and T > MIC and the efficacy of dalbavancin against S. pneumoniae ATCC 10813 (top panel) and S. aureus ATCC 29213 (bottom panel) in the thighs of neutropenic mice over a 144-h treatment period. Each symbol represents the mean log10 CFU/thigh values for four thighs.

Article Snippet: Beta-lactam resistance did not affect the in vitro potency of dalbavancin. table ft1 table-wrap mode="anchored" t5 TABLE 1. caption a7 Organism Dalbavancin MIC/MBC (mg/liter) MIC (mg/liter) Penicillin Methicillin S. pneumoniae strain 1199 0.004/0.004 1.0 1293 0.004/0.004 2.0 1325 0.008/0.008 2.0 1329 0.008/0.008 2.0 ATCC 10813 0.03/0.03 0.008 S. aureus strain ATCC 25923 0.12/0.50 0.12 33591 0.12/0.25 >8.0 31005 0.06/0.12 0.12 MRSA 0.06/0.25 >8.0 Smith 0.06/0.25 0.12 307109 0.06/0.12 >8.0 Open in a separate window In vitro activity of dalbavancin against S. pneumoniae and S. aureus strains

Techniques:

Journal:

Article Title: In Vivo Pharmacodynamic Activity of the Glycopeptide Dalbavancin ▿

doi: 10.1128/AAC.01264-06

Figure Lengend Snippet: Efficacy of dalbavancin against S. pneumoniae and S. aureus

Article Snippet: Beta-lactam resistance did not affect the in vitro potency of dalbavancin. table ft1 table-wrap mode="anchored" t5 TABLE 1. caption a7 Organism Dalbavancin MIC/MBC (mg/liter) MIC (mg/liter) Penicillin Methicillin S. pneumoniae strain 1199 0.004/0.004 1.0 1293 0.004/0.004 2.0 1325 0.008/0.008 2.0 1329 0.008/0.008 2.0 ATCC 10813 0.03/0.03 0.008 S. aureus strain ATCC 25923 0.12/0.50 0.12 33591 0.12/0.25 >8.0 31005 0.06/0.12 0.12 MRSA 0.06/0.25 >8.0 Smith 0.06/0.25 0.12 307109 0.06/0.12 >8.0 Open in a separate window In vitro activity of dalbavancin against S. pneumoniae and S. aureus strains

Techniques:

Journal:

Article Title: In Vivo Pharmacodynamic Activity of the Glycopeptide Dalbavancin ▿

doi: 10.1128/AAC.01264-06

Figure Lengend Snippet: Impact of neutrophils on in vivo efficacy of dalbavancin against S. pneumoniae

Article Snippet: Beta-lactam resistance did not affect the in vitro potency of dalbavancin. table ft1 table-wrap mode="anchored" t5 TABLE 1. caption a7 Organism Dalbavancin MIC/MBC (mg/liter) MIC (mg/liter) Penicillin Methicillin S. pneumoniae strain 1199 0.004/0.004 1.0 1293 0.004/0.004 2.0 1325 0.008/0.008 2.0 1329 0.008/0.008 2.0 ATCC 10813 0.03/0.03 0.008 S. aureus strain ATCC 25923 0.12/0.50 0.12 33591 0.12/0.25 >8.0 31005 0.06/0.12 0.12 MRSA 0.06/0.25 >8.0 Smith 0.06/0.25 0.12 307109 0.06/0.12 >8.0 Open in a separate window In vitro activity of dalbavancin against S. pneumoniae and S. aureus strains

Techniques: In Vivo

Journal:

Article Title: In Vivo Pharmacodynamic Activity of the Glycopeptide Dalbavancin ▿

doi: 10.1128/AAC.01264-06

Figure Lengend Snippet: Dose-response relationship for dalbavancin in the neutropenic murine thigh and lung infection models against S. pneumoniae ATCC 10813 over a 6-day treatment period. Each datum point represents the mean and standard deviation for either two mice (four thighs [triangles]) or three mice (lungs [circles]).

Article Snippet: Beta-lactam resistance did not affect the in vitro potency of dalbavancin. table ft1 table-wrap mode="anchored" t5 TABLE 1. caption a7 Organism Dalbavancin MIC/MBC (mg/liter) MIC (mg/liter) Penicillin Methicillin S. pneumoniae strain 1199 0.004/0.004 1.0 1293 0.004/0.004 2.0 1325 0.008/0.008 2.0 1329 0.008/0.008 2.0 ATCC 10813 0.03/0.03 0.008 S. aureus strain ATCC 25923 0.12/0.50 0.12 33591 0.12/0.25 >8.0 31005 0.06/0.12 0.12 MRSA 0.06/0.25 >8.0 Smith 0.06/0.25 0.12 307109 0.06/0.12 >8.0 Open in a separate window In vitro activity of dalbavancin against S. pneumoniae and S. aureus strains

Techniques: Infection, Standard Deviation

Journal: Breast cancer research and treatment

Article Title: Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43

doi: 10.1007/s10549-013-2755-z

Figure Lengend Snippet: CONSORT: NSABP B-43 IHC immunohistochemistry, FISH fluorescence in situ hybridization

Article Snippet: For patients who have hormone receptor-positive DCIS, hormonal therapy should be given for a minimum of 5 years by investigator discretion ( , CONSORT; , Schema). fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window caption a7 CONSORT: NSABP B-43 IHC immunohistochemistry, FISH fluorescence in situ hybridization fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window caption a7 Schema NSABP B-43

Techniques: Immunohistochemistry, Fluorescence, In Situ Hybridization

Journal: Breast cancer research and treatment

Article Title: Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43

doi: 10.1007/s10549-013-2755-z

Figure Lengend Snippet: Schema NSABP B-43

Article Snippet: For patients who have hormone receptor-positive DCIS, hormonal therapy should be given for a minimum of 5 years by investigator discretion ( , CONSORT; , Schema). fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window caption a7 CONSORT: NSABP B-43 IHC immunohistochemistry, FISH fluorescence in situ hybridization fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window caption a7 Schema NSABP B-43

Techniques: